AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson’s, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.
Analyst recommendations
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson’s, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.
Daiwa America lowered shares of AbbVie (NYSE:ABBV – Free Report) from a strong-buy rating to a hold rating in a research report report published on Thursday,Zacks.com reports. Several other ...
AbbVie Inc (ABBV, Financial) announced on December 7, 2024, the updated results from its Phase 1b/2 EPCORE NHL-2 trial, which evaluates the investigational drug epcoritamab in combination with ...
Quantbot Technologies LP bought a new position in shares of AbbVie Inc. (NYSE:ABBV – Free Report) during the 3rd quarter, HoldingsChannel reports. The firm bought 771 shares of the company’s ...